Detalhe da pesquisa
1.
Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.
J Pharmacokinet Pharmacodyn
; 41(2): 127-39, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24578187
2.
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Bioorg Med Chem Lett
; 20(20): 6096-9, 2010 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20817449
3.
Antisense inhibition of 11betahydroxysteroid dehydrogenase type 1 improves diabetes in a novel cortisone-induced diabetic KK mouse model.
Biochem Biophys Res Commun
; 365(4): 740-5, 2008 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-18029262
4.
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Neoplasia
; 20(1): 1-11, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29172076
5.
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.
Blood Adv
; 1(15): 1088-1100, 2017 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296751
6.
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Endocrinology
; 147(2): 1044-53, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16269450
7.
Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat.
Endocrinology
; 143(8): 2880-5, 2002 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12130551
8.
Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.
Cancer Med
; 3(3): 462-71, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24573979
9.
Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
Mol Cancer Ther
; 11(1): 57-65, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22084163